PCYC–1102

The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01105247 (Accessed November 3, 2017)

PCYC–1112, RESONATE

The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01578707  (Accessed November 3, 2017)

PCYC–1115 RESONATE-2, PCYC-1116

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01724346  (Accessed November 3, 2017)

CLL3001, HELIOS

PCYC–1126E/ECOG

PCYC–1130, iLLUMINATE

An open-label, multi-center randomized, phase 3 study of ibrutinib combined with obinutuzumab versus chlorambucil in combination with obinutuzumab in subjects with treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02264574 (Accessed November 3, 2017)

CLL3011, GLOW

A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/record/NCT03462719 (Accessed July, 2018)

PCYC–1142, CAPTIVATE

This study is to determine the clinical minimum residual disease (MRD) response with the combination of ibrutinib plus venetoclax in subjects with treatment-naive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02910583 (Access November 3, 2017)

PCYC–1104

The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01236391 (Accessed November 3, 2017)

MCL3002, SHINE

The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01776840  (Accessed November 3, 2017)

PCYC–1143, SYMPATICO

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT03112174  (Accessed November 3, 2017)

PCYC–1118e

In this research study, the investigators are testing the safety and efficacy of PCI-32765 as a treatment option for relapsed or refractory Waldenstrom's Macroglobulinemia.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01614821  (Accessed November 3, 2017)

PCYC–1127, iNNOVATE

The purpose of this study is to evaluate the safety and efficacy of Ibrutinib in combination with Rituximab in subjects with Waldenström's Macroglobulinemia.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02165397  (Accessed November 3, 2017)

PCYC–1121

Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subjects with relapsed/refractory Marginal Zone Lymphoma (MZL).

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01980628 (Accessed November 3, 2017)

PCYC–1141, PERSPECTIVE

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subjects with follicular lymphoma.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02947347 (Accessed November 3, 2017)

FLR3001, SELENE

The purpose of this study is to evaluate the efficacy and safety of ibrutinib administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01974440 (Accessed November 3, 2017)

PCYC–1123

PCYC–1129

The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02195869 (Accessed November 3, 2017)

PCYC–1140, INTEGRATE

To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02959944  (Accessed November 3, 2017)

LYM3003, SPARKLE

LYM3003, SPARKLE, is a randomized, open-label, safety and efficacy study of ibrutinib in pediatric and young adult patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma and is set up to be conducted in two parts. In Part 1, the purpose is to evaluate the consistency of pharmacokinetics of ibrutinib in pediatric participants versus/as compared to adults. In Part 2, the purpose is to assess efficacy (event-free survival [EFS]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02703272 (Accessed September, 2018)

PCYC–1137, RESOLVE

This is a phase 2/3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02436668  (Accessed November 3, 2017)

PCYC–1128

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in selected advanced gastrointestinal and genitourinary tumors.

Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT02599324 (Accessed November 3, 2017)